Male Contraception

  • Bradley D. Anawalt
  • Stephanie T. Page
Living reference work entry
Part of the Endocrinology book series (ENDOCR)


About 25% of couples worldwide use vasectomy or condoms for contraception. Vasectomy should be considered irreversible, and condoms are often used incorrectly (leading to high failure rates) and may decrease sexual pleasure. These are the only available effective male-based contraceptives, and the high usage of these methods despite the above drawbacks indicates that there is a need for novel forms of male contraception. The novel male contraceptives furthest along in development are male hormonal contraceptives. In efficacy trials, male hormonal contraceptives have failure rates of < 5% – rates that are superior to male condoms and compare favorable to female hormonal contraceptives. A long-acting injectable formulation of testosterone plus a progestin is most likely to be the first commercially available male hormonal contraceptive. In clinical trials, such long-acting formulations have been demonstrated to be safe, effective, and reversible. The most common side effects are acne, gain, and modest suppression of serum high density lipoprotein concentrations. There have been some concerns about possible adverse mood effects, too. The most promising nonhormonal contraceptive is reversible inhibition of sperm under guidance (more widely known as RISUG). RISUG involves the injection of a solution of styrene maleic anhydride into the vasa deferentia where the solution solidifies into a plug. RISUG is reversible; the plug can be dissolved with a vasal injection of sodium bicarbonate. Other potential nonhormonal male contraceptives include gamendazole, molecular inhibitors of an epididymal protease inhibitor (Eppin), and inhibitors of testis-specific aldehyde dehydrogenase. The development of novel hormonal and nonhormonal male contraceptives would be useful for men and for heterosexual couples who would like additional options for family planning.


Male hormonal contraception Male contraception Vasectomy Condoms 


  1. Amory JK, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ. Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception. 2007;75:218–23.CrossRefPubMedGoogle Scholar
  2. Amory JK, Muller CH, Shimshoni AJ, Isoherranen N, Paik J, Moreb JS, et al. Suppression of spermatogenesis by bisdichloroacetyldiamines is mediated by inhibition of testicular retinoic acid biosynthesis. J Androl. 2011;32:111–9.CrossRefPubMedGoogle Scholar
  3. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999;20:407–14.PubMedGoogle Scholar
  4. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ, Bremner WJ. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Fertil Steril. 2000;74:707–14.CrossRefPubMedGoogle Scholar
  5. Anderson R, Wu FCW. Comparison between testosterone enanthate-induced azoosperm and oligozoosperma in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab. 1996;81:896–901.PubMedGoogle Scholar
  6. Anderson RA, Kinniburgh D, Baird DT. Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab. 2002;87:3640–9.CrossRefPubMedGoogle Scholar
  7. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11betamethyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J Steroid Biochem Mol Biol. 2008;110:214–22.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, et al. The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alphareduction to exert their maximal androgenic effects. J Steroid Biochem Mol Biol. 2010;122:212–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-term effects of dimethandrolone 17beta-undecanoate and 11beta-methyl-19-17beta-dodecylcarbonate on body composition, bone mineral density, serum gonadotropins, and androgenic/anabolic activity in castrated male rats. J Androl. 2011;32:183–92.CrossRefPubMedGoogle Scholar
  10. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab. 1993;77:427–32.PubMedGoogle Scholar
  11. Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD. Enzymes of andro- gen formation and degradation in the human prostate. Ann N Y Acad Sci. 1990;595:53–66.CrossRefPubMedGoogle Scholar
  12. Batár I, Sivin I. State-of-the-art of non-hormonal methods of contraception: I. Mechanical barrier contraception. Eur J Contracept Reprod Health Care. 2010;15(2):67–88.CrossRefPubMedGoogle Scholar
  13. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996;81:757–62.PubMedGoogle Scholar
  14. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod. 2001;16:2570–7.CrossRefPubMedGoogle Scholar
  15. Behre HM, Zitzmann M, Anderson RA, Handelsman DJ, Lestari SW, McLachlan RI, et al. Efficacy and safety of an injectable combination hormonal contraceptive for men. J Clin Endocrinol Metab. 2016. in press.Google Scholar
  16. Beri R, Kumar N, Savage T, Benalcazar L, Sundaram K. Estrogenic and progestational activity of 7alpha-methyl-19-nortestosterone, a synthetic androgen. J Steroid Biochem Mol Biol. 1998;67:275–83.CrossRefPubMedGoogle Scholar
  17. Brady BM, Walton M, Hollow N, Kicman AT, Baird DT, Anderson RA. Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception. Hum Reprod. 2004;19:2658–67.CrossRefPubMedGoogle Scholar
  18. Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D, et al. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod. 2006;21:285–94.CrossRefPubMedGoogle Scholar
  19. Buchter D, von Eckardstein S, von Eckardstein A, Kamischke A, Simoni M, Behre HM, et al. Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception. J Clin Endocrinol Metab. 1999;84:1244–9.PubMedGoogle Scholar
  20. Chaki SP1, Das HC, Misro MM. A short-term evaluation of semen and accessory sex gland function in phase III trial subjects receiving intravasal contraceptive RISUG. Contraception. 2003;67(1):73–8.CrossRefPubMedGoogle Scholar
  21. Daniels K, Daugherty J, Jones J, Mosher W. Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013. Natl Health Stat Report. 2015;86:1–14.Google Scholar
  22. D’Anna LH, Korosteleva O, Warner L, Douglas J, Paul S, Metcalf C, et al. Factors associated with condom use problems during vaginal sex with main and nonmain partners. Sex Transm Dis. 2012;39:687–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Darroch JE. Trends in contraceptive use. Contraception. 2013;8:259–63.CrossRefGoogle Scholar
  24. Drake MJ, Mills IW, Cranston D. On the chequered history of vasectomy. BJU Int. 1999;84:475–81.CrossRefPubMedGoogle Scholar
  25. von Eckardstein S, Noe G, Brache V, Nieschlag E, Croxatto H, Alvarez F, et al. A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab. 2003;88:5232–9.CrossRefGoogle Scholar
  26. Fennell C, Sartorius G, Ly LP, Turner L, Liu PY, Conway AJ, Handelsman DJ. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men. Clin Endocrinol (Oxf). 2010;73:102–9.Google Scholar
  27. Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, Leder BZ. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369:1011–22.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Fu H, Darroch JE, Haas T, Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plan Perspect. 1999;31:56–84.CrossRefGoogle Scholar
  29. Gallo MF, Grimes DA, Lopez LM, Schulz KF. Nonlatex versus latex male condoms for contraception. Cochrane Database Syst Rev. 2006:CD003550.Google Scholar
  30. Giannou FK, Tsiara CG, Nikolopoulos GK, Talias M, Benetou V, Kantzanou M, et al. Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples. Expert Rev Pharmacoecon Outcomes Res. 2016;16:489–99.CrossRefPubMedGoogle Scholar
  31. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab. 2002;87:3562–72.CrossRefPubMedGoogle Scholar
  32. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, et al. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab. 2003;88:562–8.CrossRefPubMedGoogle Scholar
  33. Gu YQ, Tong JS, Ma DZ, Wang XH, Yuan D, Tang WH, et al. Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab. 2004;89:2254–62.CrossRefPubMedGoogle Scholar
  34. Gu Y, Liang X, Wu W, Liu M, Song S, Cheng L, et al. Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J Clin Endocrinol Metab. 2009;94:1910–5.CrossRefPubMedGoogle Scholar
  35. Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J, et al. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. J Androl. 2004;25:720–7.CrossRefPubMedGoogle Scholar
  36. Hair WM, Kitteridge K, O’Connor DB, Wu FC. A novel male contraceptive pill-patch combination: oral desogestrel and transdermal testosterone in the suppression of spermatogenesis in normal men. J Clin Endocrinol Metab. 2001;86:5201–9.CrossRefPubMedGoogle Scholar
  37. Handelsman DJ, Farley TM, Peregoudov A, Waites GM. Factors in nonuniform suppression of azoospermia by testosterone enanthate in normal men. World Health Organization Task Force on methods for the regulation of male fertility. Fertil Steril. 1995;63:125–33.CrossRefPubMedGoogle Scholar
  38. Heinemann K, Saad F, Wiesemes M, White S, Heinemann LA. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod. 2005a;20:549–56.CrossRefPubMedGoogle Scholar
  39. Heinemann K, Saad F, Wiesemes M, Heinemann LA. Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J Androl. 2005b;26:155–62.CrossRefPubMedGoogle Scholar
  40. Heller CG, Moore DJ, Paulsen CA. Suppression of spermatogenesis and chronic toxicity in men by a new series of bis(dichloroacetyl) diamines. Toxicol Appl Pharmacol. 1961;3:1–11.CrossRefPubMedGoogle Scholar
  41. Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ. A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotroins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab. 2004;89:5959–65.CrossRefPubMedGoogle Scholar
  42. Herrel LA, Goodman M, Goldstein M, Hsiao W. Outcomes of microsurgical vasovasostomy for vasectomy reversal: a meta-analysis and systematic review. Urology. 2015;85:819–25.CrossRefPubMedGoogle Scholar
  43. Huber D. No-scalpel vasectomy: the transfer of a refined surgical technique from China to other countries. Adv Contracept. 1989;5:217–8.CrossRefPubMedGoogle Scholar
  44. Ilani N, Roth MY, Amory JK, Swerdloff RS, Dart C, Page ST, et al. A new combination of testosterone and nestorone transdermal gels for male hormonal contraception. J Clin Endocrinol Metab. 2012;97:3476–86.CrossRefPubMedPubMedCentralGoogle Scholar
  45. Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, et al. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab. 2002;87:530–9.CrossRefPubMedGoogle Scholar
  46. Kelleher S, Howe C, Conway AJ, Handelsman DJ. Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol. 2004;60:420–8.CrossRefGoogle Scholar
  47. Kinniburgh D, Anderson RA, Baird DT. Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl. 2001;22:88–95.PubMedGoogle Scholar
  48. Kinniburgh D, Zhu H, Cheng L, Kicman AT, Baird DT, Anderson RA. Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men. Hum Reprod. 2002;17:1490–501.CrossRefPubMedGoogle Scholar
  49. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception. 2008;77:10–21.CrossRefPubMedGoogle Scholar
  50. Kubba A, Guillebaud J, Anderson R, MacGregor E. Contraception. Lancet. 2000;356:1913–9.CrossRefPubMedGoogle Scholar
  51. LaMorte A, Kumar N, Bardin CW, Sundaram K. Aromatization of 7α-methyl-19-nortestosterone by human placental microsomes in vitro. J Steroid Biochem Mol Biol. 1994;48:297–304.CrossRefPubMedGoogle Scholar
  52. Levy DA, Khouader S, Leynadier F. Allergy to latex condoms. Allergy. 1998;53:110–2.CrossRefGoogle Scholar
  53. Li L, Shao J, Wang X. Percutaneous no-scalpel vasectomy via one puncture in China. Urol J. 2014;11:1452–6.PubMedGoogle Scholar
  54. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet. 2006;367(9520):1412–20.CrossRefPubMedGoogle Scholar
  55. Liu PY, Swerdloff RS, Anawalt BD, Anderson RA, Bremner WJ, Elliesen J, et al. Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J Clin Endocrinol Metab. 2008;93:1774–83.CrossRefPubMedPubMedCentralGoogle Scholar
  56. Lohiya NK, Alam I, Hussain M, Khan SR, Ansari AS. RISUG: an intravasal injectable male contraceptive. Indian J Med Res. 2014;140(Suppl):S63–72. Review.PubMedPubMedCentralGoogle Scholar
  57. Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, et al. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000;15:637–45.CrossRefPubMedGoogle Scholar
  58. Martinez GM, Chandra A, Abma JC, Jones J, Mosher WD. Fertility, contraception, and fatherhood: data on men and women from cycle 6 (2002) of the 2002 National Survey of Family Growth. Vital Health Stat 23. 2006;26:1–142.Google Scholar
  59. McLachlan RI, O’Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM, et al. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab. 2002;87:546–56.CrossRefPubMedGoogle Scholar
  60. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C. Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab. 2004;89:142–9.CrossRefPubMedGoogle Scholar
  61. McMahon AJ, Buckley J, Taylor A, Lloyd SN, Deane RF, Kirk D. Chronic testicular pain following vasectomy. Br J Urol. 1992;69:188–91.CrossRefPubMedGoogle Scholar
  62. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, et al. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab. 1996;81:3018–23.PubMedGoogle Scholar
  63. Meriggiola MC, Bremner WJ, Costantino A, Pavani A, Capelli M, Flamigni C. An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertil Steril. 1997;68:844–50.CrossRefPubMedGoogle Scholar
  64. Meriggiola MC, Costantino A, Saad F, D’Emidio L, Morselli Labate AM, Bertaccini A, et al. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab. 2005;90:2005–14.CrossRefPubMedGoogle Scholar
  65. Meriggiola MC, Cerpolini S, Bremner WJ, Mbizvo MT, Vogelsong KM, Martorana G, et al. Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. Hum Reprod. 2006;21:2033–40.CrossRefPubMedGoogle Scholar
  66. Mommers E, Kersemaekers WM, Elliesen J, Kepers M, Apter D, Behre HM, et al. Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:2572–80.CrossRefPubMedGoogle Scholar
  67. Mosher WD, Jones J. Use of contraception in the United States: 1982–2008. Vital Health Stat. 2010;23:23.Google Scholar
  68. Newby KV, Brown KE, French DP, Wallace LM. Which outcome expectancies are important in determining young adults’ intentions to use condoms with casual sexual partners? A cross-sectional study. BMC Public Health. 2013;13:133–41.CrossRefPubMedPubMedCentralGoogle Scholar
  69. Nieschlag E. 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. October 22–23, 2006. Contraception. 2007;75:166–7.CrossRefPubMedGoogle Scholar
  70. Nieschlag E, Kumar N, Sitruk-Ware R. 7alpha-methyl-19-nortestosterone (MENTR): the population council’s contribution to research on male contraception and treatment of hypogonadism. Contraception. 2013;87:288–95.CrossRefPubMedGoogle Scholar
  71. O’Donnell L, Nicholls PK, O’Bryan MK, McLachlan RI, Stanton PG. Spermiation: the process of sperm release. Spermatogenesis. 2011;1:14–35.CrossRefPubMedPubMedCentralGoogle Scholar
  72. Oduwole OO, Vydra N, Wood NE, Samanta L, Owen L, Keevil B, Donaldson M, Naresh K, Huhtaniemi IT. Overlapping dose responses of spermatogenic and extragonadal testosterone actions jeopardize the principle of hormonal male contraception. FASEB J. 2014;28:2566–76.CrossRefPubMedPubMedCentralGoogle Scholar
  73. O’Rand MG, Widgren EE, Sivashanmugam P, Richardson RT, Hall SH, French FS, et al. Reversible immunocontraception in male monkeys immunized with eppin. Science. 2004;306:1189–90.CrossRefPubMedGoogle Scholar
  74. O’Rand MG, Silva EJ, Hamil KG. Non-hormonal male contraception: a review and development of an Eppin based contraceptive. Pharmacol Ther. 2016;157:105–11.CrossRefPubMedGoogle Scholar
  75. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab. 2006;91:4374–80.CrossRefPubMedGoogle Scholar
  76. Page ST, Kalhorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK. Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl. 2007;28:734–41.CrossRefPubMedGoogle Scholar
  77. Page ST, Amory JK, Bremner WJ. Advances in male contraception. Endocr Rev. 2008;29:465–93.CrossRefPubMedPubMedCentralGoogle Scholar
  78. Pile JM, Barone MA. Demographics of vasectomy – USA and international. Urol Clin North Am. 2009;36:295–305.CrossRefPubMedGoogle Scholar
  79. Population Reference Bureau. Family planning worldwide 2008 data sheet. 2008. New York City, New York.
  80. Ringheim K. Evidence for the acceptability of an injectable hormonal method for men. Fam Plan Perspect. 1995;27:123–8.CrossRefGoogle Scholar
  81. Roth MY, Nya-Ngatchou JJ, Lin K, Page ST, Anawalt BD, Matsumoto AM, et al. Androgen synthesis in the gonadotropin-suppressed human testes can be markedly suppressed by ketoconazole. J Clin Endocrinol Metab. 2013;98:1198–206.CrossRefPubMedPubMedCentralGoogle Scholar
  82. Roth MY, Shih G, Ilani N, Wang C, Page ST, Bremner WJ, Swerdloff RS, Sitruk-Ware R, Blithe DL, Amory JK. Acceptability of a transdermal gel-based male hormonal contraceptive in a randomized controlled trial. Contraception. 2014;90:407–12.CrossRefPubMedPubMedCentralGoogle Scholar
  83. Sharlip ID, Belker AM, Honig S, Labrecque M, Marmar JL, Ross LS, et al. Vasectomy: AUA guideline. J Urol. 2012;188:2482–91.CrossRefPubMedGoogle Scholar
  84. Shih G, Turok DK, Parker WJ. Vasectomy: the other (better) form of sterilization. Contraception. 2011;83:310–5.CrossRefPubMedGoogle Scholar
  85. Sjogren B, Gottlieb C. Testosterone for male contraception during one year: attitudes, well-being and quality of sex life. Contraception. 2001;64:59–65.CrossRefPubMedGoogle Scholar
  86. Soufir JC, Meduri G, Ziyyat A. Spermatogenetic inhibition in men taking a combination of oral medroxyprogesterone acetate and percutaneous testosterone as a male contraceptive method. Hum Reprod. 2011;26:1708–14.CrossRefPubMedGoogle Scholar
  87. Steiner MJ, Dominik R, Rountree RW, Nanda K, Dorflinger LJ. Contraceptive effectiveness of a polyurethane condom and a latex condom: a randomized controlled trial. Obstet Gynecol. 2003;101:539–47.PubMedGoogle Scholar
  88. Surampudi P, Page ST, Swerdloff RS, Nya-Ngatchou JJ, Liu PY, Amory JK, et al. Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive. Andrology. 2014;2:579–87.CrossRefPubMedPubMedCentralGoogle Scholar
  89. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, et al. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 1998;88:4659–67.Google Scholar
  90. Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, et al. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 and EEF1A1, and stimulates II1a transcription in rat Sertoli cells. Biol Reprod. 2008a;78:1139–52.CrossRefPubMedGoogle Scholar
  91. Tash JS, Attardi B, Hild SA, Chakrasali R, Jakkaraj SR, Georg GI. A novel potent indazole carboxylic acid derivative blocks spermatogenesis and is contraceptive in rats after a single oral dose. Biol Reprod. 2008b;78:1127–38.CrossRefPubMedGoogle Scholar
  92. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83:397–404.CrossRefPubMedPubMedCentralGoogle Scholar
  93. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, et al. Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab. 2003;88:4659–67.CrossRefPubMedGoogle Scholar
  94. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125(1–2):23–31.CrossRefPubMedGoogle Scholar
  95. World Health Organization. WHO/CONRAD technical consultation on nonoxynol-9, World Health Organization, Geneva, 9–10 October 2001: summary report. Reprod Health Matters. 2002;10:175–81.CrossRefGoogle Scholar
  96. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336:955–9.CrossRefGoogle Scholar
  97. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65:821–9.CrossRefGoogle Scholar
  98. Youssef H. The history of the condom. J R Soc Med. 1993;86:226–8.PubMedPubMedCentralGoogle Scholar
  99. Zhang L, Shah IH, Liu Y, Vogelsong KM. The acceptability of an injectable, once-a-month male contraceptive in China. Contraception. 2006;73:548–53.CrossRefPubMedGoogle Scholar
  100. Zhao R, Wu JQ1, Li YY, Zhou Y, Ji HL, Li YR. Efficacy of a combined contraceptive regimen consisting of condoms and emergency contraception pills. BMC Public Health. 2014;14:354–63.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of Medicine- Metabolism, Endocrinology and NutritionUniversity of WashingtonSeattleUSA

Personalised recommendations